Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HLUN-A.CO
Strong BuyFull HouseAPPROVEH. Lundbeck A/S · Healthcare · Denmark · $6.3B · Avg Vol: $1M/d
Lundbeck is a pure-play CNS (Central Nervous System) specialist with high recurring revenue from established psychiatric and neurological therapeutics. Its defensive moat in complex, long-cycle drug development creates high barriers to entry, making it an ideal anchor in a high-interest-rate environment where investors flee to high-margin, asset-light staples.
COMPANY DESCRIPTION
H. Lundbeck A/S is a global biopharmaceutical company dedicated exclusively to restoring brain health through the development of innovative treatments for psychiatric and neurological disorders. Its portfolio includes leading therapies for depression, schizophrenia, migraine, and Parkinson's disease, supported by a robust global commercial infrastructure. Lundbeck's competitive advantage lies in its deep, specialized R&D expertise in neuroscience and its strategic partnerships with major global pharmaceutical players.
FINANCIAL SUMMARY (DKK)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.2B | 19.9B | 22.0B | 24.6B | 10.5% | 26.2B | 25.9B | 26.0B | 2.8% |
| EPS (DKK) | 9.63 | 11.51 | 15.79 | 16.05 | 18.6% | 4.00 | — | — | — |
| Shares | 199.0M | 199.0M | 199.0M | 199.0M | 0.0% | 199.0M | — | — | — |
| Debt | 5.6B | 4.2B | 16.7B | 11.7B | 27.8% | 9.5B | — | — | — |
| Equity | 20.8B | 22.0B | 25.0B | 24.9B | 6.2% | — | — | — | — |
| Op CF | 3.5B | 4.1B | 3.3B | 5.5B | 15.9% | 5.8B | — | — | — |
| Inv CF | -1.9B | -498.0M | -15.3B | -611.0M | — | — | — | — | — |
| Fin CF | -387.0M | -2.1B | 11.6B | -6.1B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HLUN-A.CO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HLUN-A.CO | H. Lundbeck A/S(you) | $6.3B | 100 | Strong Buy |
| DEMANT.CO | Demant A/S | $9.3B | 90 | Strong Buy |
| BAVA.CO | Bavarian Nordic A/S | $2.5B | 98 | Strong Buy |
| ZEAL.CO | Zealand Pharma A/S | $3.3B | 90 | Strong Buy |
| ALK-B.CO | ALK-Abelló A/S | $7.2B | 64 | Hold |
| GMAB.CO | Genmab A/S | $20.8B | 77 | Buy |
| CBHD.DE | Coloplast A/S | $16.1B | 66 | Buy |
| AMBU-B.CO | Ambu A/S | $2.9B | 60 | Hold |
| GN.CO | GN Store Nord A/S | $2.2B | 58 | Hold |
| CHEMM.CO | ChemoMetec A/S | $1.4B | 66 | Buy |
Peer medians: ROE 18.5% · P/E 25.4x · Gross margin 82.0%